JP2013166765A5 - - Google Patents

Download PDF

Info

Publication number
JP2013166765A5
JP2013166765A5 JP2013080823A JP2013080823A JP2013166765A5 JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5 JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013080823 A JP2013080823 A JP 2013080823A JP 2013166765 A5 JP2013166765 A5 JP 2013166765A5
Authority
JP
Japan
Prior art keywords
disease
natalizumab
subject
medicament according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013080823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013166765A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013166765A publication Critical patent/JP2013166765A/ja
Publication of JP2013166765A5 publication Critical patent/JP2013166765A5/ja
Pending legal-status Critical Current

Links

JP2013080823A 2004-04-01 2013-04-08 ステロイド節約剤およびそれを使用する方法 Pending JP2013166765A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55812004P 2004-04-01 2004-04-01
US60/558,120 2004-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007506536A Division JP2007531761A (ja) 2004-04-01 2005-03-30 ステロイド節約剤およびそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2013166765A JP2013166765A (ja) 2013-08-29
JP2013166765A5 true JP2013166765A5 (enExample) 2015-03-19

Family

ID=34972924

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007506536A Pending JP2007531761A (ja) 2004-04-01 2005-03-30 ステロイド節約剤およびそれを使用する方法
JP2013080823A Pending JP2013166765A (ja) 2004-04-01 2013-04-08 ステロイド節約剤およびそれを使用する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007506536A Pending JP2007531761A (ja) 2004-04-01 2005-03-30 ステロイド節約剤およびそれを使用する方法

Country Status (17)

Country Link
US (2) US20050260193A1 (enExample)
EP (1) EP1734997B1 (enExample)
JP (2) JP2007531761A (enExample)
AU (1) AU2005232571A1 (enExample)
CA (1) CA2561364C (enExample)
DK (1) DK1734997T3 (enExample)
ES (1) ES2554754T3 (enExample)
HU (1) HUE026236T2 (enExample)
IL (1) IL178302A (enExample)
MY (1) MY162179A (enExample)
NO (1) NO20064979L (enExample)
NZ (1) NZ594476A (enExample)
PL (1) PL1734997T3 (enExample)
PT (1) PT1734997E (enExample)
SI (1) SI1734997T1 (enExample)
TW (1) TWI462744B (enExample)
WO (1) WO2005099776A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
WO2006055871A2 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
AU2012202575B2 (en) * 2004-11-19 2014-11-20 Biogen Ma Inc. Treatment for Multiple Sclerosis
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
JP5854513B2 (ja) 2009-08-03 2016-02-09 インキューブ ラブズ， エルエルシー 腸管内でインクレチン生産を刺激するための嚥下可能カプセルおよび方法
US8759284B2 (en) 2009-12-24 2014-06-24 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2011108638A1 (ja) * 2010-03-04 2011-09-09 大日本住友製薬株式会社 炎症性腸疾患用薬剤
HUE050858T2 (hu) 2010-04-16 2021-01-28 Biogen Ma Inc VLA-4 ellenes antitestek
CA2805270C (en) * 2010-06-04 2021-03-09 The Brigham And Women's Hospital, Inc. Treatment of inflammatory disorders
ES2997080T3 (en) 2010-10-25 2025-02-14 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2667854T3 (es) * 2011-07-07 2018-05-14 Holy Stone Healthcare Co., Ltd. Composición para uso en el tratamiento y la prevención de trastornos relacionados con la inflamación
EP3492099A1 (en) * 2011-11-23 2019-06-05 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
JP7470646B2 (ja) * 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
US20230181714A1 (en) * 2020-05-27 2023-06-15 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1999040939A1 (en) * 1998-02-10 1999-08-19 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
EP1300401B1 (en) * 2000-06-30 2009-12-09 Dainippon Sumitomo Pharma Co., Ltd. Thiazole derivatives for use as antiinflammatories
US6794506B2 (en) * 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
IL157706A0 (en) 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
EP1389108A2 (en) * 2001-05-09 2004-02-18 Novartis AG Methods for selective immunomodulation using pimecrolimus
US20030008844A1 (en) * 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
DK1436427T3 (da) * 2001-10-19 2008-12-08 Chru Tours Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
US6878518B2 (en) * 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
US7576101B2 (en) 2003-01-24 2009-08-18 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same

Similar Documents

Publication Publication Date Title
JP2013166765A5 (enExample)
JP6654967B2 (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
RU2770050C2 (ru) Способ лечения с применением традипитанта
Ding et al. Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study
Keystone et al. Adalimumab therapy in rheumatoid arthritis
CN116261463A (zh) 治疗痛风的方法
Lunn et al. Diagnosis and treatment in inflammatory neuropathies
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
Santomasso Anticancer drugs and the nervous system
Shukla et al. Novel non-biologic targets for inflammatory bowel disease
Puig et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up
Seni et al. Advancements in ulcerative colitis management: a critical assessment of etrasimod therapy
Lolis et al. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
JP2025514978A (ja) 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用
CN106659738B (zh) 阿尔茨海默病(ad)的治疗和预防
AU2022230300A1 (en) Treatment and/or reduction of occurrence of migraine
CANSEVER et al. Successful Rapid Desensitization of Two Teenagers with Rituximab Hypersensitivity.
Cianci et al. Subcutaneous immunoglobulin in infantile chronic inflammatory demyelinating polyneuropathy: a case report
Nobile-Orazio et al. Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders
Boucher et al. Emerging Drugs for Amyotrophic Lateral Sclerosis
WO2024155810A1 (en) Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy
Schreiber et al. T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4)
Sorbera et al. hu1124
Fasanmade et al. T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease